Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$60.06 - $78.77 $4.77 Million - $6.26 Million
79,445 Added 131.78%
139,729 $10.6 Million
Q1 2024

May 15, 2024

BUY
$59.79 - $81.05 $3.6 Million - $4.89 Million
60,284 New
60,284 $4.12 Million

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.13B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track First Light Asset Management, LLC Portfolio

Follow First Light Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Light Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on First Light Asset Management, LLC with notifications on news.